Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Peter

Showing results (501-510 of 536) with videos related to

Pageof 54
Sort By:
JCI Insight|October 5, 2016
Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areataMilène Kennedy Crispin, Justin M Ko, Brittany G Craiglow, et al.
The Science of the Total Environment|July 7, 2019
Mushroom productivity trends in relation to tree growth and climate across different European forest biomesE Collado, J A Bonet, J J Camarero, et al.
The Journal of Investigative Dermatology|September 18, 2020
QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical StudyOlivier Bornert, Marieke Hogervorst, Pauline Nauroy, et al.
Science Translational Medicine|December 11, 2024
Repurposing an epithelial sodium channel inhibitor as a therapy for murine and human skin inflammationMårten C G Winge, Mazen Nasrallah, Leandra V Jackrazi, et al.
The New England Journal of Medicine|December 14, 2022
Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis BullosaShireen V Guide, Mercedes E Gonzalez, I Sinem Bağcı, et al.
Cells|September 14, 2024
The Relationship between HERV, Interleukin, and Transcription Factor Expression in ZIKV Infected versus Uninfected Trophoblastic CellsAnderson Luís da Costa, Paula Prieto-Oliveira, Márcia Duarte-Barbosa, et al.
Experimental Dermatology|January 24, 2017
Unique mouse monoclonal antibodies reactive with maturation-related epitopes on type VII collagenTaihei Hayakawa, Yoshiaki Hirako, Kwesi Teye, et al.
JCI Insight|October 4, 2019
Phase 1/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosaShaundra Eichstadt, Melissa Barriga, Anusha Ponakala, et al.
Annals of Internal Medicine|October 8, 2008
Stool DNA and occult blood testing for screen detection of colorectal neoplasiaDavid A Ahlquist, Daniel J Sargent, Charles L Loprinzi, et al.
Lancet (London, England)|June 26, 2025
Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trialJean Y Tang, M Peter Marinkovich, Karen Wiss, et al.
Pageof 54

Showing results (501-510 of 536) with videos related to

Sort By:
Pageof 54
JCI Insight|October 5, 2016
Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areataMilène Kennedy Crispin, Justin M Ko, Brittany G Craiglow, et al.
The Science of the Total Environment|July 7, 2019
Mushroom productivity trends in relation to tree growth and climate across different European forest biomesE Collado, J A Bonet, J J Camarero, et al.
The Journal of Investigative Dermatology|September 18, 2020
QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical StudyOlivier Bornert, Marieke Hogervorst, Pauline Nauroy, et al.
Science Translational Medicine|December 11, 2024
Repurposing an epithelial sodium channel inhibitor as a therapy for murine and human skin inflammationMårten C G Winge, Mazen Nasrallah, Leandra V Jackrazi, et al.
The New England Journal of Medicine|December 14, 2022
Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis BullosaShireen V Guide, Mercedes E Gonzalez, I Sinem Bağcı, et al.
Cells|September 14, 2024
The Relationship between HERV, Interleukin, and Transcription Factor Expression in ZIKV Infected versus Uninfected Trophoblastic CellsAnderson Luís da Costa, Paula Prieto-Oliveira, Márcia Duarte-Barbosa, et al.
Experimental Dermatology|January 24, 2017
Unique mouse monoclonal antibodies reactive with maturation-related epitopes on type VII collagenTaihei Hayakawa, Yoshiaki Hirako, Kwesi Teye, et al.
JCI Insight|October 4, 2019
Phase 1/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosaShaundra Eichstadt, Melissa Barriga, Anusha Ponakala, et al.
Annals of Internal Medicine|October 8, 2008
Stool DNA and occult blood testing for screen detection of colorectal neoplasiaDavid A Ahlquist, Daniel J Sargent, Charles L Loprinzi, et al.
Lancet (London, England)|June 26, 2025
Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trialJean Y Tang, M Peter Marinkovich, Karen Wiss, et al.
Pageof 54